2007 Facility of the Year Category winners!

COOK PHARMICA, LLC
Facility of the Year Award Winner in Facility Integration

Project: Project Phoenix
Location: Bloomington, Indiana, USA
Size: 124,000 sq ft.
Cost: $70 million USD

Project Information: The growing trend in cell culture-based therapeutics inspired Cook Group, Inc., to transform an abandoned factory into an innovative new contract manufacturing facility. The result was Cook Pharmica's Project Phoenix facility located in Bloomington, Indiana, USA. Cook Pharmica is currently focused on mammalian cell culture-based production of Active Pharmaceutical Ingredients (API). In addition to its manufacturing train offering scale-up capabilities to 5,000L, Cook Pharmica also provides contract development and analytical services.

Product: Contract development and manufacturing services of mammalian cell culture-based API

Key Project Participants:

Timeline:

 

GENENTECH
Facility of the Year Award Winner in Project Execution

Project:   Oceanside Product Operations (NIMO)
Location:   Oceanside, California, USA
Size:   500,000 sq. ft.
Budget:   $375 million USD Base Project

Project Information:   Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes biotherapeutics for significant unmet medical needs. Upon U.S. Food and Drug Administration (FDA) licensure, which is expected in the first half of 2007, the facility will have 90,000 liters of capacity for the production of Avastin® (bevacizumab), a therapeutic antibody for the treatment of various forms of cancer.  The six-building, 500,000-square-foot, master-planned campus features manufacturing, laboratory/office space, a warehouse, central utilities, and a "spine" inter-connecting space.  The Oceanside Product Operations facility currently employs approximately 580 people.

Product:  Avastin® (bevacizumab)

Key Project Participants:  

Timeline:  

 

 

SHANGHAI ROCHE PHARMACEUTICALS LIMITED
Facility of the Year Award Winner in Project Execution Regional Excellence

Project: Shanghai High Potent Production Project (SHiP)
Location: Shanghai, China
Size: Total Facility 2,100 sq. m.
Budget: 16.64 million USD

Project Information: The Shanghai High Potent Production Project (SHiP) was based on a modest budget and the entire project comprised construction of a new building for the production of highly active medicines with strict containment. The facility was created to manufacture tablets and capsules for the China market, and export of products for the prevention of organ rejection in transplant recipients and for the treatment of specific forms of cancer.

Products: Cellcept® (Mycophenolate Mofetil), Xeloda® (Capecitabine), and Furtulon® (Doxifluridine)

Key Project Participants:

Timeline:

 

 

TAIYO PHARMACEUTICAL INDUSTRY CO., LTD.
Facility of the Year Award Winner in Equipment Innovation

Project: Unit Factory Building PFS Manufacturing Line
Location: Takayama-city, Japan
Size: 11,744 m 2
Budget: Construction Cost: JPY 4,580,000,000; Equipment Cost: Primary Work - JPY 3,290,000,000 and Secondary Work - JPY 4,850,000,000

Project Information: Consistent with its low cost strategy and in accordance with its mid- to long-term management strategy, Taiyo Pharmaceutical Industry Co., Ltd. began the in-house project of manufacturing pre-filled syringes (PFS) at its Unit Factory Building PFS Manufacturing facility. The project currently produces a total of six products, including four plastic syringe containers and two glass syringe containers. In addition to the in-house syringe project, two other manufacturing lines have been successfully completed and produce pre-filled syringes equipped with high-speed type isolators.

Product: PFS Manufacturing Line

Key Project Participants:

Timeline:

 

 

VETTER PHARMA-FERTIGUNG GMBH & CO. KG
Facility of the Year Award Winner in Process Innovation

Project: New Facility Ravensburg Vetter South (RVS)
Location: Ravensburg, Germany
Size: Total facility 16,000 m 2 with 2,920 m 2 production area
Budget: 100 million euros

Project Information: The New Facility Ravensburg Vetter South took 36 months from start of detailed design to complete validation. Vetter started operation of the facility in October 2006 and its production site currently has two filling lines, which will be expanded to four in the near future. The facility is the result of more than a quarter of a century of expertise in prefilling. Automation was planned throughout the building, from door openers, to the use of the brand new Restricted Access Barrier System (RABS) on the filling lines. It features maximum automation; high standards of sterility, safety, and quality; self-sufficient production site with its own utility and power supply; unique production lines; and a capacity of 90 million units per year. RVS was designed to meet all of the challenges that technicians and scientists are faced with when aseptically filling syringes, cartridges, and vials.

Products: Contract manufacturing of innovative pharmaceutical products for parenteral administration

 

Key Project Participants:

Timeline: